Researchers are showing immense interest in cancer immunotherapy, specifically immunotherapy based on immune checkpoints such as programmed cell death 1 (PD-1), programmed death ligand 1 (PDL1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Here, CTLA4 is linked to cancer.